Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ...

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF), a type of heart disease that is notoriously difficult ...

Javed Butler, MD, MPH, MBA, discusses the additional benefits of combining finerenone with sodium-glucose cotransporter-2 inhibitors for treating heart failure (HF) with midrange ejection fraction ...

These findings have led to strong guideline recommendations for their use in HFrEF. However, their efficacy in HFmrEF or ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

HFrEF= Heart Failure Reduced Ejection Fraction; HFpEF= Heart Failure Preserved Ejection Fraction; CKD= Chronic Kidney Disease; CVD + DM= Cardiovascular Disease with Diabetes Mellitus. This is an ASCO ...

Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Cytokinetics (CYTK – Research Report). The associated price ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.

Thus, semaglutide is on a trajectory to finally provide a long-awaited treatment for HFpEF patients. According to GlobalData’s Pharma Intelligence Center, there are five Phase III candidates ...